Diligence memo · auto-generated · as of July 2, 2026
Islet Sciences, Inc
Islet Sciences, Inc looks under-valued against its niche peers and is dormant on financing cadence.
Businessfiled
Islet Sciences, Inc operates in Biotechnology, based in RALEIGH.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Islet Sciences, Inc has raised $8.5M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Series A (a $4.0M–$15M round).
Largest single filing: $4.2M on 2012-03-20.
Most recent recorded round closed around 2013-12-04.
Valuation (modeled)modeled
Provath models Islet Sciences, Inc at approximately $80M (range $2.4M–$437M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.51× the median modeled value of Series A Biotechnology companies in 2013–2015 (111 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 5 months.
Last raise 12.6 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 3.2× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 53% of Biotechnology peers (4293 compared).
Modeled value ranks above 54% of those peers.
Closest niche peers: Dnanexus, Inc., Foresight Biotherapeutics, Inc., AuraSense Therapeutics, LLC, Zyomyx Inc, Champions Oncology, Inc..
Peoplefiled
10 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.